EUS- and US- Guided Biopsy for Pancreatic Lesion

Launched by TIAN'AN JIANG · Aug 17, 2025

Keywords

ClinConnect Summary

This clinical trial is studying two different ways to take a small tissue sample (called a biopsy) from the pancreas to help diagnose pancreatic cancer. The two methods use special imaging tools—endoscopic ultrasound (EUS), which involves a thin tube with an ultrasound device passed into the digestive tract, and regular ultrasound (US), which uses sound waves from outside the body—to guide the needle to the right spot in the pancreas. The goal is to see which method works better at accurately diagnosing pancreatic problems and which one is safer with fewer complications.

People who might be eligible for this study are adults who have a pancreatic lesion (a suspicious area in the pancreas) and have had a biopsy procedure between January 2017 and December 2023 at certain hospitals in China. To be included, patients needed to have at least 12 months of follow-up after the procedure to check on their health. Participants can expect that their biopsy will be done using either the EUS or US method, and the study will compare the results and any side effects. This study is not yet recruiting, but it aims to help doctors understand the best way to diagnose pancreatic cancer with the least risk.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Between January 2017 and December 2023, 2663 consecutive patients with focal pancreatic disease underwent 2729 procedures for pancreatic tissue acquisition from focal pancreatic lesions at seven university teaching hospitals in China.
• Exclusion Criteria:
• • Patients were excluded from the study if they had less than 12 months of follow-up, were lost to follow-up, had incomplete follow-up data, or underwent intraoperative biopsy or fluid aspiration.